Pirfenidone and Advanced Liver Fibrosis.

PHASE2CompletedINTERVENTIONAL
Enrollment

122

Participants

Timeline

Start Date

August 1, 2019

Primary Completion Date

August 31, 2020

Study Completion Date

December 31, 2020

Conditions
Liver FibrosisChronic Liver Disease
Interventions
DRUG

Pirfenidone

Treatment consist of 600 mg tablets of a prolonged-released formulation of Pirfenidone. Patients are instructed to take medication orally, every 12 h, after breakfast and dinner.

OTHER

Standard of care

All participants will require to adhere to a standard of care including nutritional support, quarterly medical evaluation to review lab results and adjust medications, bi-annual Fibrotest, FibroScan and liver ultrasound, and annual upper-gastrointestinal endoscopy.

Trial Locations (1)

Unknown

Liver Clinic 1, Mexico City

All Listed Sponsors
lead

Grupo Mexicano para el Estudios de las Enfermedades Hepaticas

OTHER

NCT04099407 - Pirfenidone and Advanced Liver Fibrosis. | Biotech Hunter | Biotech Hunter